Chimeric receives $1.62M advance on FY26 R&D tax incentive
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The funding, amounting to a significant sum, will support ongoing clinical trial activities and general working capital. This agreement with Endpoints Capital allows early access to funds secured against the expected tax incentive from the Australian Taxation Office. The repayment of this facility is scheduled to occur after the anticipated receipt of the tax incentive.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- Investor Presentation
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Later from Chimeric Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - CHM
- Trading Halt
- CHM ceases enrolment in Phase 1 trial and Company update
- Appendix 4E and Preliminary Final Report
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics